Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page's revision tag changed from v3.5.3 to v3.5.4. This indicates a minor update to the ClinicalTrials.gov interface with no impact on trial data or listings.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s displayed software/version identifier was incremented from “v3.5.2” to “v3.5.3,” indicating a minor site update without altering the trial record information.SummaryDifference0.2%

- Check30 days agoChange DetectedThe page history shows a new site revision (v3.5.2) replacing the previous revision (v3.5.0).SummaryDifference0.1%

- Check59 days agoChange DetectedFooter revision updated from v3.4.3 to v3.5.0; no changes to study data or page content.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded Revision: v3.4.3 to the history and removed Revision: v3.4.2.SummaryDifference0.1%

- Check94 days agoChange DetectedRevision: v3.4.2 was added and the v3.4.1 notice about government funding was removed; these are administrative updates that do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.